MSB News: BioCardia (BCDA) Gains FDA Nod for ARDS Cell Therapy Study - 14th Apr 2022, 12:25am

[annb0t]

BioCardia, Inc. BCDA announced that the FDA has approved its investigational new drug (“IND”) application to initiate a clinical study on its pre-clinical pipeline candidate, BCDA-04. The company is planning to initiate a phase I/II study that will evaluate the candidate in patients recovering from acute respiratory distress syndrome (“ARDS”) due to COVID-19.

The company is planning to start the study in the third quarter of 2022.

The phase I portion of the study will evalu...

>>> Read more: BioCardia (BCDA) Gains FDA Nod for ARDS Cell Therapy Study